Search

Sanofi SA

Uždarymo kaina

SektoriusSveikatos priežiūra

81.04 0.07

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.98

Max

81.19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.9B

5.8B

Pardavimai

11B

21B

P/E

Sektoriaus vid.

15.922

34.393

Pelnas, tenkantis vienai akcijai

1.59

Dividendų pajamingumas

4.88

Pelno marža

27.234

Darbuotojai

82,878

EBITDA

2.2B

2.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+33.26% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.88%

2.54%

Kitas uždarbis

2025-10-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.1B

100B

Ankstesnė atidarymo kaina

80.97

Ankstesnė uždarymo kaina

81.04

Naujienos nuotaikos

By Acuity

34%

66%

90 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 10:06; UTC

Pagrindinės rinkos jėgos

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

2025-07-31 06:00; UTC

Uždarbis

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

2025-07-30 10:20; UTC

Uždarbis

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

2025-07-30 05:31; UTC

Uždarbis

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

2025-08-06 05:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Completes the Acquisition of Vigil Neuroscience

2025-08-06 05:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

2025-08-01 13:16; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 12:40; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-07-31 08:15; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

2025-07-31 05:56; UTC

Rinkos pokalbiai
Uždarbis

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

2025-07-31 05:30; UTC

Uždarbis

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Business Operating Profit EUR2.46B

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Adj EPS EUR1.59

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Net Pft EUR3.94B

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

2025-07-31 05:30; UTC

Uždarbis

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

2025-07-31 05:30; UTC

Uždarbis

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Sales EUR9.99B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Backs 2025 EPS Adj View

2025-07-31 05:30; UTC

Uždarbis

Sanofi Narrows 2025 Sales View

2025-07-31 05:30; UTC

Uždarbis

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

2025-07-30 07:48; UTC

Rinkos pokalbiai
Uždarbis

Santander Results Get Lukewarm Reaction -- Market Talk

2025-07-30 06:41; UTC

Rinkos pokalbiai
Uždarbis

Santander's Strategic Investments in Focus -- Market Talk

2025-07-30 04:52; UTC

Uždarbis

Santander End-2Q CET1 Ratio 13%

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

33.26% į viršų

12 mėnesių prognozė

Vidutinis 107.845 EUR  33.26%

Aukščiausias 124 EUR

Žemiausias 90 EUR

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

14 ratings

10

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

91.3 / 96.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

90 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.